IGC Pharma Publishes Study In European Society Of Medicine For Impact Of CYP2C9 Genetic Polymorphism On Pharmacokinetics Of Delta 9 Tetrahydrocannabinol
Portfolio Pulse from Benzinga Newsdesk
IGC Pharma has published a study in the European Society of Medicine on the impact of CYP2C9 genetic polymorphism on the pharmacokinetics of Delta 9 Tetrahydrocannabinol. This study aims to enhance the understanding of treatments for Alzheimer's patients, potentially leading to more effective treatments.
June 10, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IGC Pharma's study on CYP2C9 genetic polymorphism and Delta 9 THC could lead to more effective treatments for Alzheimer's, potentially boosting the company's reputation and future revenues.
The publication of this study in a reputable journal could enhance IGC Pharma's credibility in the medical community, potentially leading to increased interest and investment in their Alzheimer's treatments. This could positively impact their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100